ImmunoGen, Inc. Announces Conference Call to Discuss its First Quarter Fiscal Year 2016 Financial Results
Get Alerts IMGN Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Tuesday, October 27, 2015, to discuss ImmunoGen's financial results for the three-month period ended September 30, 2015. Management also will provide an update on the Company.
To access the live call by phone, dial 913-905-3226; the conference ID is 9613638. The call also may be accessed through the Investors section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through November 10, 2015.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The Company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche’s Kadcyla® is the first marketed product with ImmunoGen’s ADC technology. More information about the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151013005239/en/
For Investors & Media:
ImmunoGen, Inc.
Carol Hausner,
781-895-0600
[email protected]
Source: ImmunoGen, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Hertz Q1 results to be more 'challenging' after CEO change, but there's hope: MS
- Tenaya Therapeutics, Inc. (TNYA) Tops Q4 EPS by 3c
- Bit Digital (BTBT) Reports FY EPS of $0.12
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!